Dual GIP/GLP-1 receptor agonist
Tirzepatide: brands, cost & how it works
Tirzepatide is a once-weekly dual GIP/GLP‑1 receptor agonist sold as Zepbound for chronic weight management (and obstructive sleep apnea) and Mounjaro for type 2 diabetes. By activating two gut hormones it drives greater appetite suppression; in SURMOUNT-1 it produced up to about 20.9% average weight loss at 72 weeks.
The brands
Tirzepatide brands compared
Tirzepatide is the same molecule across every brand below — the differences are the FDA-approved indication, dose range, and price. Scored on efficacy, safety, cost, and access.
- Top pick1Editor's Choice
FDA-approved tirzepatide for weight loss
- Highest reported weight loss of any approved GLP-1 (avg ~21% in SURMOUNT-1)
- Dual GIP + GLP-1 mechanism
- FDA-approved for OSA + obesity (2024)
FDA-approvedBrand-name—/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$549/mo · 10mg+$150 - 2